AAO News
The latest clinical breakthroughs, practice management updates, and national advocacy alerts directly from the American Academy of Ophthalmology.
Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease
Lifitegrast is an integrin antagonist that decreases T-cell–mediated inflammation associated with dry eye disease (DED). We report the results of OPUS-2, a phase III study evaluating the efficacy and safety of lifitegrast compared with placebo for the treatment of DED.
Powered by Versicherungsvergleich
Our Industry Partners
Empowering Excellence in Ophthalmology
We extend our deepest gratitude to our Platinum, Gold, and Silver partners. Your generous support fuels our mission to advance medical education, advocate for patient safety, and foster breakthrough innovations across West Virginia.
West Virginia Academy of Eye Physicians and Surgeons — advancing quality eye care through education, advocacy, and community awareness.
About
Resources
Advocacy